Logo

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

Share this

Merck Presents New Data of Keytruda (pembrolizumab) in Three Studies for the Treatment of Melanoma at SMR 2021

Shots:

  • The new data from KEYNOTE-006/587/716 studies evaluate Keytruda in patients with melanoma. Patients were eligible for transition to KEYNOTE-587 for extended follow-up after KEYNOTE-006
  • The exploratory 7yrs. follow-up data of the KEYNOTE-006 study showed m-OS (32.7mos. for Keytruda & 15.9mos. for ipilimumab; 7yrs. OS rates (37.8% & 25.3%), an exploratory analysis showed that Keytruda was associated with improved clinical outcomes regardless of BRAF status & 2 others
  • The KEYNOTE-716 trial showed an improvement in RFS compared to PBO with a 39% reduction in risk of disease recurrence or death. At IA2, patients treated with Keytruda had a recurrence or died (14.8% vs 23.5%)

  Ref: Gilead | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions